Trial · NCT00105027
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | CRVO Observation | 5 | Participants | ||
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | CRVO 1 mg Dose Triamcinolone Acetonide | 22 | -6.4 to 4.1 | Participants | |
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | CRVO 4 mg Dose Triamcinolone Acetonide | 21 | -6.3 to 4.0 | Participants | |
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | BRVO Standard Care | 35 | 1.1 to 7.3 | Participants | |
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | BRVO 1 mg Dose Triamcinolone Acetonide | 31 | 2.8 to 8.6 | Participants | |
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | BRVO 4 mg Dose Triamcinolone Acetonide | 34 | 0.9 to 7.2 | Participants | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | CRVO Observation | -12.1 | 95% Confidence Interval -17.1 to -7.1 | letters read | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | CRVO 1 mg Dose Triamcinolone Acetonide | -1.2 | 95% Confidence Interval -6.4 to 4.1 | letters read | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | CRVO 4 mg Dose Triamcinolone Acetonide | -1.2 | 95% Confidence Interval -6.3 to 4.0 | letters read | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | BRVO Standard Care | 4.2 | 95% Confidence Interval 1.1 to 7.3 | letters read | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | BRVO 1 mg Dose Triamcinolone Acetonide | 5.7 | 95% Confidence Interval 2.8 to 8.6 | letters read | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | BRVO 4 mg Dose Triamcinolone Acetonide | 4.0 | 95% Confidence Interval 0.9 to 7.2 | letters read | |
| Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | CRVO Observation | -277 | Inter-Quartile Range -418 to -40 | um | |
| Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | CRVO 1 mg Dose Triamcinolone Acetonide | -196 | Inter-Quartile Range -390 to -62 | um | |
| Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | CRVO 4 mg Dose Triamcinolone Acetonide | -261 | Inter-Quartile Range -407 to -79 | um | |
| Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | BRVO Standard Care | -224 | Inter-Quartile Range -411 to -67 | um | |
| Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | BRVO 1 mg Dose Triamcinolone Acetonide | -149 | Inter-Quartile Range -279 to -18 | um | |
| Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | BRVO 4 mg Dose Triamcinolone Acetonide | -170 | Inter-Quartile Range -304 to -63 | um | |
| Adverse Ocular Outcomes | CRVO Observation | Initiation of IOP-lowering medications | 7 | events | |
| Adverse Ocular Outcomes | CRVO 1 mg Dose Triamcinolone Acetonide | Initiation of IOP-lowering medications | 18 | events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00105027/results